

**ASX Announcement**

**13 November 2024**

## **OncoSil Medical Investor Webinar**

**The webinar will update investors on recent and pending developments  
in the commercialisation strategy for OncoSil Medical's unique MedTech**

**OncoSil Medical Limited (ASX:OSL) Chief Executive Officer & Managing Director Nigel Lange will present  
an investor webinar on Friday 15 November 2024.**

The webinar will be hosted by The Capital Network's Julia Maguire.

In his presentation, Nigel Lange will highlight:

- Recent milestones achieved in OncoSil Medical's ongoing efforts to become a leading treatment option for pancreatic cancer – both in Australia and overseas
- The commercial significance of these milestones, the recently announced G-BA approval for the OncoSil™ device included as well as the MDR approval
- Key objectives of OncoSil Medical's near and medium-term growth strategy.

### **OncoSil Medical Investor Webinar Registration Details:**

**DATE:** Friday 15 November 2024

**TIME:** 11.00-11.45 AM AEDT

**FORMAT:** Zoom

**Please register in advance using the following link:**

[https://us02web.zoom.us/webinar/register/WN\\_65xZe6h9TJqPqmUwMhHlkg](https://us02web.zoom.us/webinar/register/WN_65xZe6h9TJqPqmUwMhHlkg)

After registering, you will receive a confirmation email containing information about joining the webinar.

**Ends.**

## Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

### For further information, please contact:

<b>Mr. Nigel Lange</b> CEO & Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 30 300 149 3043	<b>Mr. Christian Dal Cin</b> CFO & Company Secretary E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a> T: +61 3 9824 5254	<b>Ms. Julia Maguire</b> <b>The Capital Network</b> Media and Investor Enquiries E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a> T: +61 2 8999 3699
--	--	---

### About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

**References:** 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>